Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $(0.36) by 141.67 percent. This is a 120.27 percent increase over losses of $(0.74) per share from the same period last year. The company reported quarterly sales of $268.295 million which beat the analyst consensus estimate of $205.185 million by 30.76 percent. This is a 60.85 percent increase over sales of $166.797 million the same period last year.